Clinical bottom line
Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool to dissect cancer heterogeneity at unprecedented resolution, enabling identification of distinct tumor cell subpopulations and microenvironmental components that drive disease progression and therapy resistance. Recent studies demonstrate that scRNA-seq can reveal recurrent intra-tumoral heterogeneity patterns and characterize cancer-associated fibroblast diversity, informing potential therapeutic targets. While promising, clinical translation remains limited by technical complexity and interpretative challenges. Integration with bulk transcriptomic data and spatial profiling may enhance utility in precision oncology (Weng et al., 2026; Kazakova et al., 2024; Zhang et al., 2023).
What the evidence shows
Weng et al. (2026) provide compelling evidence that recurrent intra-tumoral heterogeneity is a hallmark of metastatic prostate cancer. Using scRNA-seq, they identified distinct tumor cell clones with differential gene expression profiles linked to metastatic potential and therapeutic resistance, underscoring the dynamic evolution of tumor ecosystems.
Kazakova et al. (2024) focus on cancer-associated fibroblasts (CAFs), a key stromal component influencing drug resistance. Their single-cell transcriptomic analyses reveal multiple CAF subsets with distinct functional roles, suggesting that targeting specific fibroblast populations could overcome microenvironment-mediated therapy failure.
Zhang et al. (2023) integrate bulk RNA-seq with scRNA-seq data in colorectal cancer patients, demonstrating that single-cell resolution refines understanding of tumor heterogeneity beyond bulk analyses. This approach identified rare cell populations potentially responsible for treatment resistance and relapse.
Van Kuijk et al. (2023), although focused on fibroblasts in cardiovascular contexts, illustrate how aging and systemic factors modulate fibroblast heterogeneity, a concept translatable to tumor microenvironment studies.
Grausenburger et al. (2024) review recent advances in single-cell and spatial profiling in bladder cancer, highlighting how these technologies elucidate tumor architecture and immune interactions, with implications for immunotherapy.
Caveats and uncertainty
scRNA-seq data interpretation is complex due to technical noise, batch effects, and challenges in distinguishing malignant from non-malignant cells.
High costs and bioinformatic demands limit routine clinical application.
Spatial context is often lost in dissociative scRNA-seq, though emerging spatial transcriptomics may address this.
Heterogeneity observed may vary by tumor type, stage, and prior treatment, complicating generalizability.
Clinical trials validating scRNA-seq-guided therapeutic decisions are scarce.
How this may change practice
Incorporation of scRNA-seq into research and clinical workflows can refine tumor classification and identify novel therapeutic targets.
Combined single-cell and spatial profiling may enable personalized treatment strategies by mapping tumor-immune-stromal interactions.
Integration with bulk sequencing data enhances robustness and clinical relevance of heterogeneity analyses.
Pathology laboratories may increasingly adopt single-cell technologies to complement histopathology and molecular diagnostics.
Ongoing advances in computational tools and cost reduction will facilitate broader clinical implementation.